John Vaeth, MD
Psychiatry · Baltimore, MDNPI 1992848345
Payments from drug & device makers
Across 2,693 payments — averaging $762.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$873K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$384K
- Otsuka America Pharmaceutical, Inc.$365K
- Axsome Therapeutics, Inc.$209K
- Vanda Pharmaceuticals Inc.$98K
- Ironshore Pharmaceuticals Inc.$58K
- plus $67K from 13 others
What the payments were for
- Consulting fees$78,2814%
- Speaking & faculty fees$1,623,08679%
- Travel & lodging$305,97015%
- Food & beverage$45,3802%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,101 | $872,826 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 402 | $383,923 |
| Otsuka America Pharmaceutical, Inc. | 367 | $364,505 |
| Axsome Therapeutics, Inc. | 250 | $208,887 |
| Vanda Pharmaceuticals Inc. | 121 | $97,924 |
| Ironshore Pharmaceuticals Inc. | 104 | $57,918 |
| Takeda Pharmaceuticals U.S.A., Inc. | 60 | $31,586 |
| Tris Pharma Inc | 21 | $13,792 |
| Supernus Pharmaceuticals, Inc. | 41 | $11,598 |
| Neos Therapeutics, LP | 102 | $3,862 |
| Sage Therapeutics, LLC | 3 | $2,384 |
| Johnson & Johnson | 18 | $1,407 |
| Aytu Biopharma, Inc. | 6 | $1,071 |
| Lundbeck LLC | 78 | $740 |
| Sentynl Therapeutics, Inc. | 2 | $127 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $95 |
| Shire North American Group Inc | 5 | $84 |
| Sunovion Pharmaceuticals Inc. | 6 | $66 |
| Adlon Therapeutics L.p. | 2 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$854,952
- CAPLYTA$379,151
- REXULTI$360,820
- Auvelity$204,939
- Fanapt$96,661
- JORNAY PM$56,502
- VYVANSE$17,634
- Quillichew ER$13,522
- Quillivant$13,522
- Dyanavel XR$13,522
- TRINTELLIX$13,300
- QELBREE$5,606
- Adzenys XR-ODT$1,900
- Cotempla XR-ODT$1,900
- SPRAVATO$1,041
- ZolpiMist$950
How this compares
$2,052,815 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Baltimore
- Akira SawaBaltimore$5.1M
- Paul RosenbergBaltimore$1.9M
- Scott AaronsonBaltimore$1.3M
- Karen AndersonBaltimore$1.1M
- Constantine LyketsosBaltimore$1.1M
- Alan JonasBaltimore$1.1M
- Sarah HertsBaltimore$1M
- Robert LehmanBaltimore$947K
- Marc FishmanBaltimore$822K
- Adam KaplinBaltimore$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.